RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells (Q33664919)

28 July 2017

title

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells (English)

1 reference

28 July 2017

1 reference

1 reference

1 reference

Shilpi Arora

1

1 reference

28 July 2017

Kristen M Bisanz

2

1 reference

28 July 2017

Lourdes A Peralta

3

1 reference

28 July 2017

Gargi D Basu

4

1 reference

28 July 2017

Ashish Choudhary

5

1 reference

28 July 2017

Raoul Tibes

6

1 reference

28 July 2017

David O Azorsa

7

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

118

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

220-227

1 reference

28 July 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Ovarian cancer: strategies for overcoming resistance to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Expression profiling and individualisation of treatment for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

siRNAs: applications in functional genomics and potential as therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Fulfilling the promise: drug discovery in the post-genomic era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

RNA interference screening for the discovery of oncology targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Cancer proliferation gene discovery through functional genomics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Profiling essential genes in human mammary cells by multiplex RNAi screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Utilizing RNA interference to enhance cancer drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

High-throughput siRNA screening as a method of perturbation of biological systems and identification of targeted pathways coupled with compound screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Improved statistical methods for hit selection in high-throughput screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Biochemical and molecular mechanisms of cisplatin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Cisplatin: mode of cytotoxic action and molecular basis of resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Protein kinases--the major drug targets of the twenty-first century?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

DNA Damage Induces p53-dependent Down-regulation of hCHK1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

p16INK4A participates in a G1 arrest checkpoint in response to DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Role of the p38 MAPK pathway in cisplatin-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Cell cycle checkpoint signaling through the ATM and ATR kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Nonapoptotic role for Apaf-1 in the DNA damage checkpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Targeted cancer therapies based on the inhibition of DNA strand break repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

New checkpoint blockers begin human trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Mutation analysis of the ATR gene in breast and ovarian cancer families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.006

10.1016/J.YGYNO.2010.05.006

7 January 2021

Identifiers

DOI

1 reference

28 July 2017

1 reference